Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation: research article
Aims Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and associated with worse outcomes. Empagliflozin reduces cardiovascular death or HF hospitalizations and slows estimated glomerular filtration rate (eGFR) decline in patien...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2023
|
| In: |
European journal of heart failure
Year: 2023, Jahrgang: 25, Heft: 7, Pages: 970-977 |
| ISSN: | 1879-0844 |
| DOI: | 10.1002/ejhf.2861 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ejhf.2861 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2861 
|
| Verfasserangaben: | Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, Faiez Zannad, João Pedro Ferreira, Anne Pernille Ofstad, Tomoko Iwata, Martina Brueckmann, Stuart J. Pocock, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1882045076 | ||
| 003 | DE-627 | ||
| 005 | 20240307021908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240228s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.2861 |2 doi | |
| 035 | |a (DE-627)1882045076 | ||
| 035 | |a (DE-599)KXP1882045076 | ||
| 035 | |a (OCoLC)1425200500 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |0 (DE-588)1306318645 |0 (DE-627)1865923133 |4 aut | |
| 245 | 1 | 0 | |a Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation |b research article |c Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, Faiez Zannad, João Pedro Ferreira, Anne Pernille Ofstad, Tomoko Iwata, Martina Brueckmann, Stuart J. Pocock, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
| 264 | 1 | |c July 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 16. April 2023 | ||
| 500 | |a Gesehen am 28.02.2024 | ||
| 520 | |a Aims Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and associated with worse outcomes. Empagliflozin reduces cardiovascular death or HF hospitalizations and slows estimated glomerular filtration rate (eGFR) decline in patients with HF and LVEF >40%. We aimed to assess the efficacy and safety of empagliflozin in improving outcomes in patients with HF and LVEF >40% with and without AF. Methods and results In this pre-defined secondary analysis of EMPEROR-Preserved, we compared the effects of empagliflozin versus placebo on the primary and secondary endpoints and safety outcomes, stratified by baseline AF, defined as AF reported in any electrocardiogram before empagliflozin initiation or in medical history. Among 5988 patients randomized, 3135 (52%) had baseline AF; these patients were older, with worse functional class, more previous HF hospitalizations and higher natriuretic peptides compared to those without AF (all p < 0.001). After a median of 26 months, empagliflozin reduced cardiovascular death or HF hospitalization compared to placebo to a similar extent in patients with and without AF (hazard ratio [HR] 0.78 [95% confidence interval 0.66-0.93] vs. 0.78 [0.64-0.95], interaction p = 0.96). Empagliflozin also reduced total HF hospitalizations (HR 0.73 [0.57-0.94] vs. 0.72 [0.54-0.95], interaction p = 0.94) and annual eGFR decline (difference = 1.368 vs. 1.372 ml/min/1.73 m2/year, interaction p = 0.99) consistently in patients with and without AF. There was no increase in serious adverse events with empagliflozin versus placebo in patients with and without AF. Conclusions In patients with HF and ejection fraction >40%, empagliflozin reduced the risk of serious HF events and slowed the eGFR decline regardless of baseline AF. | ||
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Atrial flutter | |
| 650 | 4 | |a Empagliflozin | |
| 650 | 4 | |a Heart failure with preserved ejection fraction | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Sodium-glucose cotransporter 2 inhibitor | |
| 700 | 1 | |a Farmakis, Dimitrios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ofstad, Anne Pernille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Iwata, Tomoko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Pocock, Stuart J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan |e VerfasserIn |0 (DE-588)1078340498 |0 (DE-627)83835260X |0 (DE-576)450727793 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d Oxford : Wiley, 1999 |g 25(2023), 7 vom: Juli, Seite 970-977 |h Online-Ressource |w (DE-627)306658291 |w (DE-600)1500332-2 |w (DE-576)081985983 |x 1879-0844 |7 nnas |a Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation research article |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:7 |g month:07 |g pages:970-977 |g extent:8 |a Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation research article |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ejhf.2861 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2861 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240228 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 8 | ||
| 999 | |a KXP-PPN1882045076 |e 4493018879 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"July 2023"}],"relHost":[{"titleAlt":[{"title":"EJHF"}],"recId":"306658291","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"doi":["10.1002/(ISSN)1879-0844"],"issn":["1879-0844"],"zdb":["1500332-2"],"eki":["306658291"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"European journal of heart failure","subtitle":"journal of the Working Group on Heart Failure of the European Society of Cardiology","title":"European journal of heart failure"}],"note":["Gesehen am 07.01.25"],"disp":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation research articleEuropean journal of heart failure","pubHistory":["1.1999 -"],"origin":[{"publisher":"Oxford University Press ; Elsevier Science ; Oxford Univ. Press ; Wiley","dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisherPlace":"Oxford ; Amsterdam [u.a.] ; Oxford [u.a.] ; Oxford"}],"part":{"year":"2023","text":"25(2023), 7 vom: Juli, Seite 970-977","extent":"8","issue":"7","volume":"25","pages":"970-977"}}],"name":{"displayForm":["Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, Faiez Zannad, João Pedro Ferreira, Anne Pernille Ofstad, Tomoko Iwata, Martina Brueckmann, Stuart J. Pocock, Milton Packer, Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators"]},"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"language":["eng"],"id":{"eki":["1882045076"],"doi":["10.1002/ejhf.2861"]},"recId":"1882045076","title":[{"title_sort":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","subtitle":"research article"}],"person":[{"family":"Filippatos","display":"Filippatos, Gerasimos","roleDisplay":"VerfasserIn","role":"aut","given":"Gerasimos"},{"role":"aut","given":"Dimitrios","roleDisplay":"VerfasserIn","family":"Farmakis","display":"Farmakis, Dimitrios"},{"role":"aut","given":"Javed","roleDisplay":"VerfasserIn","display":"Butler, Javed","family":"Butler"},{"given":"Faiez","role":"aut","family":"Zannad","display":"Zannad, Faiez","roleDisplay":"VerfasserIn"},{"given":"João Pedro","role":"aut","roleDisplay":"VerfasserIn","display":"Ferreira, João Pedro","family":"Ferreira"},{"given":"Anne Pernille","role":"aut","roleDisplay":"VerfasserIn","family":"Ofstad","display":"Ofstad, Anne Pernille"},{"display":"Iwata, Tomoko","family":"Iwata","roleDisplay":"VerfasserIn","role":"aut","given":"Tomoko"},{"given":"Martina","role":"aut","family":"Brückmann","display":"Brückmann, Martina","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Stuart J.","roleDisplay":"VerfasserIn","display":"Pocock, Stuart J.","family":"Pocock"},{"roleDisplay":"VerfasserIn","family":"Packer","display":"Packer, Milton","given":"Milton","role":"aut"},{"given":"Stefan","role":"aut","display":"Anker, Stefan","family":"Anker","roleDisplay":"VerfasserIn"}],"note":["Online veröffentlicht: 16. April 2023","Gesehen am 28.02.2024"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a FILIPPATOSEMPAGLIFLO2023 | ||